Overview

24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.

Status:
Withdrawn
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare the effect of intravitreal injections of ranibizumab and aflibercept on systemic VEGF levels in DME patients in a detailed time course.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Aflibercept
Ranibizumab